Enhancer RNA-based modeling of adverse events and objective responses of cancer immunotherapy reveals associated key enhancers and target genes

Enhancer RNA-based modeling of adverse events and objective responses of cancer immunotherapy reveals associated key enhancers and target genes

Immune checkpoint inhibitors (ICI) targeting PD-1/PD-L1 or CTLA-4 are emerging and effective immunotherapy strategies. However, ICI-treated patients present heterogeneous responses and adverse events, thus demanding effective ways to assess benefit over risk before treatment. Here, by integrating pa...

Full description

Bibliographic Details
Main Authors: Mengbiao Guo, Zhiya Lu, Yuanyan Xiong
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Oncology
Subjects:
enhancer RNA (eRNA)
immune checkpoint block therapy
adverse effect
drug responses
TCGA
pan-cancer analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1048127/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1048127/full

Similar Items